Cytosar
(Cytarabine)ApprovedSmall molecule
TevaCytarabine is a chemotherapy drug used to treat certain types of blood cancers like leukemia and lymphoma by stopping cancer cells from growing and dividing.[2] Cytosar is currently approved and in use across 85 indications[4].[1]
Cytosar is one of 1073 small molecule programs targeting T-cell acute lymphoblastic leukemia. It is currently in Approved.
85
Indications
942
Total Trials
22
Active Trials
1,072
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 85 indications
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Cytosar
TevaApproved
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia32 trials
Show 29 more trials
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）
Completed·—·Phase 1/2·NCT01690507·29 enrolled
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Unknown status·IInstitut de Recherche Clinique sur les Cancers et le Sang·Phase 1·NCT00544999·21 enrolled
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
Enrolling by invitation·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT03031249·80 enrolled
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00006122·106 enrolled
Acute Lymphoblastic Leukemia27 trials
Show 24 more trials
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
Recruiting·—·Phase 1·NCT05157971·24 enrolled
Lymphoma21 trials
Show 18 more trials
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
Terminated·GGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH·Phase 1/2·NCT02983097·34 enrolled
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00003061·50 enrolled
Leukemia15 trials
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·N/A·NCT01184898·36 enrolled
Show 12 more trials
Efficacy and Safety of Chidamide in CBF Leukemia
Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT03031262·250 enrolled
Myelodysplastic Syndrome11 trials
Show 8 more trials
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00077116·31 enrolled
55 more indications
Chronic Myelogenous Leukemia9 trials
Show 6 more trials
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Withdrawn·—·Phase 1/2·NCT00002761
Bone Marrow Transplantation9 trials
Myelodysplastic Syndromes6 trials
Newly Diagnosed4 trials
Show 1 more trial
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT07486479·204 enrolled
AML3 trials
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
Completed·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT02926586·68 enrolled
Treatment3 trials
Hematologic Malignancies3 trials
Chemotherapy2 trials
Lymphoblastic Lymphoma2 trials
Stem Cell Transplant2 trials
Acute Promyelocytic Leukemia2 trials
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002701·750 enrolled
Stem Cell Transplantation2 trials
Central Nervous System Lymphoma2 trials
Mantle Cell Lymphoma2 trials
Myeloid Leukemia2 trials
Acute Leukemia2 trials
Immunodeficiency1 trial
Immunotherapy1 trial
Acute Monocytic Leukemia1 trial
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2/3·NCT05313958·43 enrolled
Diffuse Large B-Cell Lymphoma1 trial
Hematologic Cancer1 trial
CLL1 trial
T-cell non-Hodgkin lymphoma1 trial
MACE1 trial
Anaplastic Large Cell Lymphoma1 trial
Precursor B-Cell Acute Lymphoblastic Leukemia1 trial
Safety and Efficacy1 trial
Adult1 trial
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
Completed·—·Phase 1·NCT03459859·12 enrolled
Chronic Lymphocytic Leukemia1 trial
Myelofibrosis1 trial
Relapsed or Refractory1 trial
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Recruiting·—·Phase 2·NCT06316960·50 enrolled
Juvenile Myelomonocytic Leukemia1 trial
Acute Myeloid Leukaemia1 trial
Multiple Myeloma1 trial
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Unknown status·—·Phase 2·NCT00004903
Phase IB1 trial
Induction Chemotherapy1 trial
Prostate Cancer1 trial
BRAF V600E Mutation1 trial
A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation
Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2·NCT03585686·12 enrolled
Regulatory
FDA Approval Timeline[5]
Dec 21, 1987
CYTARABINE
NDA NDA016793
Apr 1, 1999
DEPOCYT
NDA NDA021041
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Cytosar drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Cytarabine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]